Ken Griffin In Med Pharmaceuticals Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in In Med Pharmaceuticals Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 12,097 shares of INM stock, worth $2,903. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,097
Previous 12,725
4.94%
Holding current value
$2,903
Previous $4,000
25.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding INM
# of Institutions
16Shares Held
463KCall Options Held
0Put Options Held
0-
Sabby Management, LLC Upper Saddle River, NJ307KShares$73,7365.39% of portfolio
-
Virtu Financial LLC New York, NY86.7KShares$20,8040.0% of portfolio
-
Baader Bank Aktiengesellschaft Unterschleissheim, 2M22.6KShares$5,4260.0% of portfolio
-
Xtx Topco LTD London, X017.8KShares$4,2760.0% of portfolio
-
Hrt Financial LP New York, NY16KShares$3,8390.0% of portfolio
About InMed Pharmaceuticals Inc.
- Ticker INM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 908,761
- Market Cap $218K
- Description
- InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in precl...